Morgagni-Stewart-Morel syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:77296OMIM:144800M85.2
Who is this for?
Show terms as
View depth
8Treatment centers

Where are you in your journey?

UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data

What is Morgagni-Stewart-Morel syndrome?

Morgagni-Stewart-Morel syndrome (also called hyperostosis frontalis interna, or HFI) is a condition where the inner surface of the frontal bone — the bone at the front of your skull — becomes thicker and denser over time. This bony overgrowth is usually harmless on its own, but it often occurs alongside a cluster of other features including obesity, excess hair growth (hirsutism), and hormonal changes. The syndrome is named after the physicians who first described it in detail. Most people with this condition are women, and symptoms typically appear or become more noticeable after middle age, often around or after menopause. The thickening of the skull bone is usually found by accident on a head X-ray or CT scan done for another reason. Some people experience headaches, dizziness, or mood changes, though it can be hard to know exactly how much of this is directly caused by the bone changes. There is no cure for Morgagni-Stewart-Morel syndrome, and treatment focuses on managing individual symptoms. Headaches may be treated with pain relievers, hormonal imbalances may be addressed by an endocrinologist, and weight management support can help with obesity. Because the condition is often mild and discovered incidentally, many people live full lives with little impact on their day-to-day activities.

Also known as:

Key symptoms:

Thickening of the bone on the inside of the foreheadHeadaches, often mild to moderateObesity or unexplained weight gainExcess hair growth on the face or body (hirsutism)Hormonal imbalances, especially related to sex hormonesDizziness or lightheadednessMood changes or depressionFatigueIrregular or absent menstrual periodsMemory or concentration difficulties

Clinical phenotype terms (30)— hover any for plain English
  • Hyperostosis frontalis internaHP:0004438
  • Abnormality of the endocrine systemHP:0000818
  • Abnormal metabolismHP:0032245
  • Psychotic episodesHP:0000725
Inheritance
Multifactorial
Caused by a mix of several genes and environmental factors
Age of Onset
Adult
Begins in adulthood (age 18 or older)
Orphanet ↗OMIM ↗NORD ↗

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for Morgagni-Stewart-Morel syndrome.

View clinical trials →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

No actively recruiting trials found for Morgagni-Stewart-Morel syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Morgagni-Stewart-Morel syndrome community →

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

No specialists are currently listed for Morgagni-Stewart-Morel syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to Morgagni-Stewart-Morel syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Morgagni-Stewart-Morel syndromeForum →

No community posts yet. Be the first to share your experience with Morgagni-Stewart-Morel syndrome.

Start the conversation →

Latest news about Morgagni-Stewart-Morel syndrome

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for Morgagni-Stewart-Morel syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How certain are you that my symptoms are related to Morgagni-Stewart-Morel syndrome, and what other conditions should be ruled out?,Do I need regular imaging to monitor the skull bone thickening, and how often?,Should I see an endocrinologist to check my hormone levels, and what treatments are available if they are abnormal?,What can I do to manage my headaches safely, and when should I be concerned about them?,Are there any lifestyle changes that could slow the progression of my symptoms?,Is there any risk that my children or other family members could develop this condition?,Are there any clinical trials or research studies I could participate in?

Common questions about Morgagni-Stewart-Morel syndrome

What is Morgagni-Stewart-Morel syndrome?

Morgagni-Stewart-Morel syndrome (also called hyperostosis frontalis interna, or HFI) is a condition where the inner surface of the frontal bone — the bone at the front of your skull — becomes thicker and denser over time. This bony overgrowth is usually harmless on its own, but it often occurs alongside a cluster of other features including obesity, excess hair growth (hirsutism), and hormonal changes. The syndrome is named after the physicians who first described it in detail. Most people with this condition are women, and symptoms typically appear or become more noticeable after middle age,

How is Morgagni-Stewart-Morel syndrome inherited?

Morgagni-Stewart-Morel syndrome follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Morgagni-Stewart-Morel syndrome typically begin?

Typical onset of Morgagni-Stewart-Morel syndrome is adult. Age of onset can vary across affected individuals.

Frequently asked questions about Morgagni-Stewart-Morel syndrome

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is Morgagni-Stewart-Morel syndrome?

    Morgagni-Stewart-Morel syndrome is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:77296, OMIM 144800). It is typically inherited as multifactorial. Age of onset is generally adult. For verified primary sources, see the UniteRare Morgagni-Stewart-Morel syndrome page.

  2. How is Morgagni-Stewart-Morel syndrome inherited?

    Morgagni-Stewart-Morel syndrome follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for Morgagni-Stewart-Morel syndrome?

    Approved treatments for Morgagni-Stewart-Morel syndrome are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials for Morgagni-Stewart-Morel syndrome?

    Active clinical trials for Morgagni-Stewart-Morel syndrome are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.

  5. How do I find a specialist for Morgagni-Stewart-Morel syndrome?

    Verified Morgagni-Stewart-Morel syndrome specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.

See full Morgagni-Stewart-Morel syndrome page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.